Petvivo Holdings, Inc. to Exhibit at the Western Veterinary Conference in Las Vegas, Nevada
PetVivo Holdings (OTCQB: PETV) announced its participation in the Western Veterinary Conference (WVC) from March 2-5, 2025, at the Mandalay Bay Convention Center in Las Vegas. The company will showcase two key products: SPRYNG® with OsteoCushion® Technology, an intra-articular injectable veterinary device using sterilized, extra-cellular matrix microparticles for joint pain management, and PrecisePRP®, a novel off-the-shelf platelet-rich plasma product.
PrecisePRP® is notable for being leucoreduced, allogeneic, and requiring no blood draw or centrifugation, offering consistent dosing of 4 billion platelets per vial. The WVC, hosting over 15,000 participants, provides PetVivo an important platform to demonstrate these innovative solutions for osteoarthritis management in equine and companion animals.
PetVivo Holdings (OTCQB: PETV) ha annunciato la sua partecipazione alla Western Veterinary Conference (WVC) che si terrà dal 2 al 5 marzo 2025 presso il Mandalay Bay Convention Center a Las Vegas. L'azienda presenterà due prodotti chiave: SPRYNG® con tecnologia OsteoCushion®, un dispositivo veterinario iniettabile intra-articolare che utilizza microparticelle di matrice extracellulare sterilizzate per la gestione del dolore articolare, e PrecisePRP®, un innovativo prodotto di plasma ricco di piastrine pronto all'uso.
Il PrecisePRP® è notevole per essere leucoredotto, allogenico e non richiedere prelievo di sangue o centrifugazione, offrendo dosaggi costanti di 4 miliardi di piastrine per fiala. La WVC, che ospita oltre 15.000 partecipanti, offre a PetVivo una piattaforma importante per dimostrare queste soluzioni innovative per la gestione dell'osteoartrite negli animali equini e da compagnia.
PetVivo Holdings (OTCQB: PETV) anunció su participación en la Western Veterinary Conference (WVC) que se llevará a cabo del 2 al 5 de marzo de 2025 en el Mandalay Bay Convention Center en Las Vegas. La empresa exhibirá dos productos clave: SPRYNG® con Tecnología OsteoCushion®, un dispositivo veterinario inyectable intraarticular que utiliza micropartículas de matriz extracelular esterilizadas para el manejo del dolor articular, y PrecisePRP®, un novedoso producto de plasma rico en plaquetas listo para usar.
El PrecisePRP® es notable por ser leucorreducido, alogénico y no requerir extracción de sangre ni centrifugación, ofreciendo una dosificación constante de 4 mil millones de plaquetas por vial. La WVC, que alberga a más de 15,000 participantes, proporciona a PetVivo una plataforma importante para demostrar estas soluciones innovadoras para el manejo de la osteoartritis en animales equinos y de compañía.
PetVivo Holdings (OTCQB: PETV)는 2025년 3월 2일부터 5일까지 라스베가스의 만달레이 베이 컨벤션 센터에서 열리는 Western Veterinary Conference (WVC)에 참여한다고 발표했습니다. 이 회사는 두 가지 주요 제품을 선보일 예정입니다: 오스테오쿠션® 기술이 적용된 SPRYNG®, 관절 통증 관리에 사용되는 멸균된 세포외 기질 미세입자를 사용하는 관절 내 주사형 수의학 장치, 그리고 PrecisePRP®, 새로운 준비된 혈소판 풍부 혈장 제품입니다.
PrecisePRP®는 백혈구가 줄어든 동종 이식으로, 혈액 채취나 원심분리가 필요하지 않으며, 바이알당 40억 개의 혈소판을 일관되게 제공하는 것이 특징입니다. 15,000명 이상의 참가자를 수용하는 WVC는 PetVivo가 말과 반려동물의 골관절염 관리에 대한 이러한 혁신적인 솔루션을 보여줄 수 있는 중요한 플랫폼을 제공합니다.
PetVivo Holdings (OTCQB: PETV) a annoncé sa participation à la Western Veterinary Conference (WVC) qui se déroulera du 2 au 5 mars 2025 au Mandalay Bay Convention Center à Las Vegas. L'entreprise présentera deux produits clés : SPRYNG® avec la technologie OsteoCushion®, un dispositif vétérinaire injectable intra-articulaire utilisant des microparticules de matrice extracellulaire stérilisées pour la gestion de la douleur articulaire, et PrecisePRP®, un nouveau produit de plasma riche en plaquettes prêt à l'emploi.
Le PrecisePRP® se distingue par le fait qu'il est leucoréduit, allogénique et ne nécessite pas de prélèvement sanguin ni de centrifugation, offrant un dosage constant de 4 milliards de plaquettes par flacon. La WVC, qui accueille plus de 15 000 participants, offre à PetVivo une plateforme importante pour démontrer ces solutions innovantes pour la gestion de l'arthrose chez les animaux équins et de compagnie.
PetVivo Holdings (OTCQB: PETV) gab seine Teilnahme an der Western Veterinary Conference (WVC) bekannt, die vom 2. bis 5. März 2025 im Mandalay Bay Convention Center in Las Vegas stattfindet. Das Unternehmen wird zwei wichtige Produkte präsentieren: SPRYNG® mit OsteoCushion® Technologie, ein intraartikuläres injizierbares veterinärmedizinisches Gerät, das sterilisierte, extrazelluläre Matrix-Mikropartikel zur Schmerzbehandlung in Gelenken verwendet, und PrecisePRP®, ein neuartiges sofort einsatzbereites Produkt mit plättchenreichem Plasma.
PrecisePRP® ist bemerkenswert, da es leucoreduziert, allogen und ohne Blutentnahme oder Zentrifugation auskommt und eine konsistente Dosierung von 4 Milliarden Thrombozyten pro Fläschchen bietet. Die WVC, die über 15.000 Teilnehmer anzieht, bietet PetVivo eine wichtige Plattform, um diese innovativen Lösungen zur Behandlung von Osteoarthritis bei Pferden und Haustieren zu präsentieren.
- Introduction of PrecisePRP®, an innovative off-the-shelf PRP product requiring no blood draw
- Guaranteed consistency in PrecisePRP® with 4 billion platelets per vial
- Exposure to 15,000+ veterinary professionals at WVC
- None.
MINNEAPOLIS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) ("PetVivo") an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for pets announced today it will be exhibiting at the Western Veterinary Conference to be held March 2nd to March 5th, 2025 at the Mandalay Bay Convention Center in Las Vegas, Nevada.
PetVivo intends to exhibit its innovative product, SPRYNG® with OsteoCushion® Technology, an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
PetVivo further intends to exhibit its new product, PrecisePRP®, a first-in-class off-the-shelf platelet-rich plasma (PRP) product designed for use by veterinarians. PrecisePRP is a leucoreduced, allogeneic, pooled, freeze-dried PRP intended to provide a species-specific source of concentrated platelets in plasma for intra-articular administration in dogs and horses. Unlike any PRP mechanical kits currently on the market, PrecisePRP™ does not require a blood draw or centrifugation making it a truly off-the-shelf product that is easy and convenient. Perhaps more important is the uniformity and consistency that PrecisePRP® guarantees. Each vial of PrecisePRP® contains a consistent dose of 4 billion platelets per vial at a concentration of 500,000 platelets per microliter and is leucoreduced with less than 1500 white blood cells per microliter.
WVC is the largest veterinary conference that services the western part of the United States, and normally plays host to more than 15,000+ participants including many of the top industry professionals.
“We are incredibly excited to participate in this year’s Western Veterinary Conference. The WVC provides us an excellent venue to speak with veterinarians about our two innovative products that may be used for the management of osteoarthritis, Spryng, with OsteoCushion Technology and PrecisePRP” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “We are looking forward to the opportunity in meeting with veterinarians at the WVC to explain the benefits of Spryng and PrecisePRP and how it may be used to enhance the lives of equine and companion animals.”
For more information about PetVivo Holdings, Inc. please contact info1@petvivo.com or visit https://petvivo.com/ and https://www.sprynghealth.com.
Conference Exhibit Details: Western Veterinary Conference (WVC)
Booth #: 1717
PetVivo Representatives Attending: Bryan Monninger, VP of Distribution and Corporate Accounts, April Boyce, VP of Sales and Marketing, and Dr. Kirsty Husby, Senior Technical Services Veterinarian
Dates:
Monday, March 3, 2025 9:00am – 5:00pm
Tuesday, March 4, 2025 9:00am – 5:00pm
Wednesday, March 5, 2025 9:00am – 2:00pm
Location: Mandalay Bay Convention Center in Las Vegas, Nevada
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQB: PETV; OTCPINK: PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG™ with OsteoCushion™ technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, is currently available for commercial sale.
For more information about PetVivo Holdings, Inc. and our revolutionary product, Spryng with OsteoCushion Technology, please contact info1@petvivo.com or visit https://petvivo.com/ or http://www.sprynghealth.com.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2023 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
What are the key features of PetVivo's (PETV) new PrecisePRP product?
When and where is PetVivo (PETV) exhibiting at the Western Veterinary Conference 2025?
How does PetVivo's (PETV) SPRYNG technology work for joint pain management?
What is the expected attendance at the 2025 Western Veterinary Conference where PETV is exhibiting?
